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Abstract 
 
CX3CR1+ macrophages in the intestinal lamina propria contribute to gut homeostasis through the 
immunomodulatory interleukin IL-10, but there is little knowledge on how these cells or the 
CX3CR1 receptor may affect colorectal carcinogenesis. In this study, we show that CX3CR1-
deficient mice fail to resolve gut inflammation despite high production of IL-10 and have increased 
colitis and adenomatous polyps in chemical and genetic models of colon carcinogenesis. 
Mechanistically, CX3CL1-mediated engagement of the CX3CR1 receptor induced upregulation of 
hemoxygenase-1 (HMOX-1), an antioxidant and anti-inflammatory enzyme. CX3CR1-deficient mice 
exhibited significantly lower expression of HMOX-1 in their adenomatous colon tissues. Combining 
LPS and CX3CL1 displayed a strong synergistic effect in vitro, but HMOX-1 levels were significantly 
lower in KO macrophages. Co-housing of wild-type and CX3CR1-/- mice during the AOM/DSS 
treatment attenuated disease severity in CX3CR1-/- mice, indicating the importance of the 
microbiome, but did not fully reinstate HMOX-1 levels and did not abolish polyp formation. In 
contrast, pharmacological induction of HMOX-1 in vivo by cobalt protoporphyrin-IX treatment 
eradicated intestinal inflammation and fully protected KO mice from carcinogenesis. Taken 
together, our results establish an essential role for the receptor CX3CR1 in gut macrophages in 
resolving inflammation in the intestine, where it helps protects against colitis-associated cancer by 
regulating HMOX-1 expression.  
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Introduction 
Gut represents a complex landscape in which commensal bacteria, harmless antigens and 
food proteins are strictly in contact with the immune system that has to be able to maintain a 
balance between the immune response and tolerance (1-3). If this crucial checkpoint is lost, the 
immune system is activated and falls in a dangerous and prolonged inflammation (4). In this 
context, mononuclear phagocytes are the most abundant population and among them 
macrophages characterized by the expression of the chemokine receptor CX3CR1 represent key 
players in this process of discrimination, by allowing a peaceful coexistence.                                               
Mucosal CX3CR1+ cells are nowadays considered a population of resident macrophages in the gut, 
continuously replenished from blood stream monocytes (5-7). Fractalkine (FKN-CX3CL1) is the only 
ligand of the chemokine receptor CX3CR1(8) and, although it has been reported to be involved in 
the attraction of monocytes/macrophages in several tissues, in the gut is not regulating monocyte 
recruitment. The current knowledge is that CX3CR1+ macrophages derive from inflammatory 
Ly6Chi CX3CR1Neg monocytes, which are recruited in the intestine via the CCR2-CCL2 axis, where 
they upregulate the CX3CR1 receptor once they have reached the tissue (6,9). In healthy 
conditions Ly6CHi monocytes mature into CX3CR1Hi macrophages expressing diverse levels of 
CX3CR1 during maturation stages. The process of maturation from CX3CR1Int to CX3CR1Hi 
macrophages is interrupted during colitis, allowing the expansion of pro-inflammatory CX3CR1Int 
macrophages that are able to face pathogens (5).      
In the gut, CX3CR1+ macrophages are able to sample luminal antigens and transfer them to 
local dendritic cells to initiate or block the immune response (10-15). Furthermore, they produce 
and sense the anti-inflammatory cytokine IL-10 in order to maintain homeostasis (5,6,16,17). 
The role of gut CX3CR1+ macrophages has been studied taking advantage of the availability 
of mice carrying the GFP reporter protein in 1 allele of the CX3CR1 gene (CX3CR1GFP/+) or in both 
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alleles (CX3CR1GFP/GFP or KO mice)(5,18). Few reports have investigated the behavior of mucosal 
CX3CR1-deficient macrophages during experiments of acute intestinal inflammation induced by 
chemical injury (Dextran Sodium Sulphate, DSS) or bacterial infections. These studies reported 
controversial results, with either higher or lower recruitment of inflammatory cells in the intestine, 
and increased or decreased inflammation (19-22). 
Our recent study clearly indicated that CX3CR1 KO mice have more severe acute colitis 
(23), however, how the CX3CR1 receptor is involved in the molecular mechanisms that regulate 
the inflammatory response is still unclear. Moreover, no data are available on the role of CX3CR1+ 
macrophages in models of prolonged inflammation, such the colitis-induced carcinogenesis (CAC).  
In this study we unveil the role of the CX3CR1 receptor in the homeostatic function of 
mucosal macrophages. We report that CX3CR1-deficient mice have a more severe disease in 
models of colon carcinogenesis, with increased inflammation sustained over-time. We 
demonstrate that ligand activation of CX3CR1 induces the production of HMOX-1, a crucial anti-
oxidant and anti-inflammatory enzyme, which decreases inflammation, protects the colonic 
mucosa and prevents the development of gut carcinogenesis. 
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Materials and methods 
Mouse Models  
Procedures involving animal care conformed to national (4D.L. N.116, G.U. 1992) and international 
laws (EEC Council Directive 2010/63/EU, OJ L 276/33, 22.09.2010). Mice were maintained in a 
specific-pathogen free facility. All efforts were made to minimize the number of animals used and 
their suffering.  All experiments were designed using C57BL/6 mice. We compared CX3CR1+/GFP 
(WT) to CX3CR1GFP/GFP (KO) and CX3CR1+/GFP-APCmin (WT) to CX3CR1GFP/GFP-APCmin (KO). Usually 8 
mice per group aged 8 weeks were used for each in vivo model. In table 1 are schematically 
resumed the different treatments. Cobalt protoporphyrin IX (coPP) was prepared in dim light due 
to its photosensibility and dissolved in sodium hydroxide (NaOH) 150mM. pH was adjusted to 7 by 
adding equal amount of hydrochloric acid (HCl) at the final concentration of 5mg/ml. The final pH 
of 7,4 was achieved by further dilution with Phoshate Buffer Saline without Calcium and 
Magnesium (PBS-/-, BioSera).  
Histological analysis 
Colons were harvested and longitudinally opened; next, they were rolled up transversely (swiss 
roll). Tissues were then fixed in 4% paraformaldehyde (PFA) and dehydrated in 30% and 40% 
sucrose in PBS−/−. Next, the colonic Ɵssues were embedded in OCT (opƟmum cuƫng temperature 
compound, Diapath) and stored at -80°C. To evaluate the histological architecture of the inflamed 
colon and calculate the percentage of the adenomatous area over the total tissue, 8 µm thick 
frozen sections were cut with cryostat and stained with hematoxylin and eosin (H&E stain). Slides 
were observed with microscope (4x) and colitis score was assessed. In order to define polyps’ 
growth, slides were scanned with VS120 Dotslide (Olympus) and analysed with OLYVIA software. 
For immunofluorescence staining, frozen tissue sections (8 µm) were incubated with the primary 
antibody(ies) in washing buffer (1 hr at room temperature) and subsequently with fluorophore-
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conjugated secondary antibody(ies) at room temperature for 1 hr in the dark (1:2000). Finally cell 
nuclei counter-stained with DAPI. Images were captured with the Olympus FluoViewTM FV1000 
confocal microscope. The acquired images were analysed with “(Fiji is just) ImageJ software”. 
Multi-channel images were split to the respective components and every channel was 
transformed into a binary image. According to the “set measure” option, the percentage of 
stained tissue in each component was calculated overall the total black background of the single 
slide. Considering the DAPI stained tissue as the entire tissue (100%), we finally calculated the 
percentage of tissue stained by every single fluorophore using the mathematical proportion: 
%DAPI:100 = %fluorophore: X 
Rna Extraction and Quantitative Real-Time PCR 
Total RNA was extracted from colon tissue. In the CAC experiments, polyps were separated from 
the rest of the colon and analysed independently. Samples were homogenized in TRIZOL (Ambion) 
using Tissue Lyser II (Quiagen). 1 μg of RNA was reverse-transcribed using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) following manufacturer’s instructions. cDNA 
analysed through quantitative Real-Time PCR, performed on Viia-7 instrument (Thermo fisher) 
using the Fast SYBR Green. GAPDH gene was amplified as internal control. The other primers are 
listed in Supplemental Materials and Figures. 
Western blot 
Quantification of Hemox-1 protein was tested in treated colons through SDS-PAGE and western 
blotting assay. Samples were harvested after sacrifice and protein extracted using Urea buffer 
(Urea 9M, 25mM Tris-HCl pH 6,8, 1mM EDTA, 10% glycerol). 25ng of total proteins were resolved 
on 10% SDS-PAGE and transferred onto Trans Blot Transfer Medium, Nitrocellulose membrane 
(Bio-Rad). After blocking, the membrane was incubated over-night with HMOX-1 antibody. After 
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the incubation with the membranes were developed with chemiluminescence reagent (Bio-Rad), 
according to the manufacturer's instructions, and visualized with Chemidoc System (Bio-Rad). 
 
Generation of Bone Marrow Derived Macrophages (BMDMs) 
Bone marrow was harvested from femura of 8- to 12-week old mice by flushing the marrow out 
with IMDM supplemented with 10% Fetal Calf Serum (FCS) and ACK (100uL/bone). Flushed cells 
were resuspended in 20 mL IMDM, 10% FCS, 1% Penicillin/Streptavidin, 1% Glutammine and let to 
adhere overnight at 37°C, 5% CO2. After incubation, cell supernatant was removed, non-adherent 
cells were spun down. Cells were stained as described and then FACS-sorted using BD FACS Aria 
and resuspended at the concentration of 0.5x106 cells/mL in complete bone marrow macrophage 
medium (IMDM, 10% FCS, 20 ng/mL M-CSF) in suspension culture dish (Corning) (10mL/dish). 
After 7 days, cells were plated at the final concentration of 2.5x105 cells/mL in 24 wells plated and 
stimulated with LPS (100ng/mL), recombinant Fractalkine (FKN, 300ng/mL) or LPS-FKN. Cells were 
lysated to recover RNA as already described, and used for qPCR analysis. 
Isolation of mononuclear cells from lamina propria 
To isolate lamina propria mononuclear cells (LPMCs), colons were then flushed of their luminal 
content, opened longitudinally and cut into 1 cm pieces. Epithelial cells were removed by 40 min 
incubation with HBSS (without Ca2+ and Mg2+) containing 5% FBS, 2 mM EDTA at 37°C, shaking at 
275 rpm. Colon pieces were then digested in HBSS-/- containing 5% FBS, 0,5 mg/ml Collagenase 
VIII (Sigma), for 40 min at 37°C shaking at 275 rpm. The obtained cell suspension was then pressed 
into a syringe needle, washed with RPMI and passed sequentially through 100 and 40 µm cell 
strainers. Cells were centrifuged for 6min at 1600 rpm, resuspended in RPMI and used for the 
subsequent analysis.  
Flow cytometry  
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Briefly, cells were harvested from colon samples of both polyps, inflamed colon and healthy 
control as described before. Cells were washed with FACS buffer (PBS -/-, 2% FBS), and incubated 
30 min at 4°C with antibodies and suspended in 350ul of FACS buffer. Immediately, cells were read 
using FACS Canto II instrument and FACS Diva software version 6.1.1 (BD Biosciences). For each 
experiment, cells were stained with appropriate isotype control antibodies to establish 
background staining before calculating the percentage of positive cells. 
Pospho-protein detection  
To detect the expression of phosphorylated protein, 2x106 cells were suspended in DMEM at 37°C 
and stimuli were added (IL-10 25ng/mL, FKN 300ng/mL) to a final volume of 300ul. Cells were 
treated for 5’, 30’ or for 120’. After the treatment, PFA were added to fix the cells. Cold methanol 
was added for 20’ to permeabilize cells and samples were stained with pSTAT3 (py705-BD) for 30’ 
at room temperature in the dark. After the incubation, cells were washed and suspended in 350ul 
of FACS buffer (PBS-/-, FBS 1%, NaN3 0,1%) and analyzed with CANTO II instrument. 
Phagocytosis Assay 
Peritoneal-elicited macrophages were harvested from WT and KO mice. Briefly, 1ml of 
thioglycolate (3% thioglycolate medium w/o dextrose, BD) was injected intra-peritoneum (IP). 
After three days, mice were sacrificed and 10 ml of cold physiologic solution were injected in the 
peritoneum, cells were collected and kept in ice. Live cells were sorted using FACS Aria instrument 
based on GFP gene reporter expression. After, 2x105 cells were plate on glass slides in 24 wells in 
DMEM overnight. In the meantime, polystyrene latex beads (Sigma-Aldrich), 3 μm in diameter 
were coated with LPS diluted 1:100 in bicarbonate buffer in a ratio of 1:10 cells/beads by 
incubating for 1h at 37°C shaking. Beads were washed once with HBSS-/- and added to cells for 1h. 
The excess of beads was washed out and cells stained and fixed with DiffQuik (medion diagnostics) 
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and mounted on glass. Beads were counted at the microscope, analysing ten fields for each 
samples. The percentage of phagocytosis was calculated as follow: n cells: n bead =100: x 
 
 
Reagents 
The following antibodies were used. Immunofluorescence: rat anti-mouse F4/80 monoclonal 
antibody (eBioscience) 1:500, Rabbit anti-human Zo-1 (Invitrogen) polyclonal antibody 1:200, 
Rabbit anti-human HMOX-1 polyclonal antibody (Bio Rad) 1:500. Western Blot: rabbit anti-mouse 
HMOX-1 antibody (proteintech) 1:600. Flow cytometry: CD45 percP (BD), CD11b pacific blue 
(eBiolegend), F4/80 PE (Serotec), Ly6G PE-cy7 (BD), Ly6C APC (BD), pSTAT3 (py705-BD).  
Microbioma profiling 
The bacterial community structure of fecal samples was determined by 16S rRNA gene profiling as 
previously described (24). In brief, a DNA fragment encompassing the variable region V3 of the 16S 
rRNA gene was amplified from fecal metagenomic DNA with the primers Probio_Uni (5’-
CCTACGGGRSGCAGCAG-3’) and Probio_Rev (5’-ATTACCGCGGCTGCT-3’) and was sequenced by 
means of Ion Torrent PGM sequencing technology (Life Technologies). Sequence reads were 
analyzed using the bioinformatic pipeline Quantitative Insights Into Microbial Ecology (QIIME) 
version 1.7.0 (25) with the GreenGenes database updated to version 13.5. Bacterial relative 
abundances in fecal sample were studied at the taxonomic levels of phylum, family, and genus. 
Details are listed in the online supplementary files.  
Statistical Analysis  
Statistical analysis was performed with GraphPad Prism 6 (GraphPad Software). To compare 
different data sets, unpaired two-tailed Student’s t test was used and results were expressed as 
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mean ± SEM for the histograms and as median, quartiles, 5th-95th percentiles for the whiskers 
box. A value of p<0.05 (*) was considered as statistically significant. 
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Results 
The chemically- induced colitis-associated cancer is more severe in CX3CR1GFP/GFP mice  
 We used the model of colitis-associated cancer (CAC) induced by the carcinogen 
azoxymethane (AOM) and Dextran Sulfate Sodium (DSS) in mice proficient and deficient for the 
chemokine receptor CX3CR1 (CX3CR1+/GFP and CX3CR1GFP/GFP mice). AOM was intra-peritoneally 
injected and a week after mice were fed with DSS, followed by water for two weeks, for a total of 
three cycles, as schematically presented in Fig. 1A. During treatment, mice were monitored for 
weight, stool consistency and bleeding, to score Disease Activity Index (DAI). After the first cycle of 
DSS, both KO and WT mice showed loss in weight and signs of bleeding, but during the recovery 
phase with water, WT mice gained weight (Supplementary Fig. S1A) and stopped bleeding, while 
KO mice failed to recover (Fig. 1B). During further cycles, the difference between WT and KO 
became even stronger, in particular for the inability of KO mice to regain weight. At the end of the 
experiment, after 70 days, colons were harvested and histologically analysed. KO mice showed 
higher colitis scores and reduced colon length (Fig. 1C), indicating they had more severe 
inflammation compared to WT mice. Consistent with this, KO mice had a significantly higher 
percentage of adenomatous polyps (Fig. 1C) and lower survival rate (Supplementary Fig. S 1B). 
Increased macrophage infiltration and cytokine production in the colons of CX3CR1GFP/GFP mice 
 By immunofluorescence of colon sections, we observed that CX3CR1-KO mice presented a 
higher number of GFPPos macrophages (Fig. 1D). Inside the adenomatous polyps, macrophages 
were GFPPos, while at the border F4/80+ cells were mostly GFPNeg (Fig. 1E), suggesting that – and in 
line with the literature – CX3CR1Hi macrophages originate from CX3CR1Neg -GFPNeg newly recruited 
monocytes. The FACS analysis on disaggregated colons confirmed that more GFP+ macrophages 
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were present in the gut of KO mice (Fig. 1F, left) and indicated that Ly6Chi inflammatory 
monocytes, but not Ly6Clow monocytes, were more abundant (Fig. 1F, middle and right). 
 We next evaluated the expression of inflammatory mediators. We dissected polyps from 
the inflamed colons and separately analysed the mRNA levels of pro-inflammatory and anti-
inflammatory cytokines. As shown in Fig. 2A, the inflamed mucosa of KO mice contained higher 
levels of TNFα, IL-6, IFNγ, IL-1β, COX2 and IL-12 (p35); IFNγ, IL-1β and IL-12 were increased also in 
the adenomatous tissue. IL-10 family members (IL-10, IL-19 and IL-20) were also over-expressed in 
the gut of KO mice (Fig. 2B) and, importantly, the IL-10R was not reduced (Supplementary Fig. S 
2A). As the homeostatic ability of CX3CR1 macrophages relies also on their response to IL-10(16), 
we verified that CX3CR1GFP/GFP macrophages were able to sense IL-10. When stimulated in vitro 
with IL-10, macrophages from KO mice correctly phosphorylated STAT3 as much as macrophages 
from WT mice (Supplementary Fig. S 2B).  Thus, the cytokine milieu of the colonic mucosa of 
CX3CR1-KO mice indicates an exacerbated inflammation, not attributable to a dysregulation of the 
IL-10 system. 
 
Inability of CX3CR1GFP/GFP mice to resolve acute inflammation  
 In view of the inability of KO mice to correctly control gut inflammation in the AOM/DSS 
model, we analysed their behaviour in the process of resolution from acute colitis. As shown in Fig. 
3A, mice were treated with 1 cycle (7 days) of DSS followed by water for 3 or 6 days. By day 10, 
WT mice started to recover and at day 13 had completely recovered from colitis and were healthy, 
while KO mice still displayed severe signs of inflammation in terms of weight loss and colon 
shortness (Fig. 3B). The expression of inflammatory mediators was high at day 10 in both WT and 
KO mice, but at day 13 the mRNA levels of TNFα, IL6, IL-1β and COX2 were decreased in WT mice, 
while KO mice still showed sustained levels, in spite of significantly higher production of IL-10 and 
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IL-20 (Fig. 3C). Colon tissues of KO mice had a more abundant infiltration of macrophages, 
especially GFP+ Mφ, and Ly6Chigh inflammatory monocytes. (Fig. 3D). Thus, KO mice are unable to 
successfully resolve inflammation in a prolonged model of colitis.  
Intestinal carcinogenesis is more severe in the double knock out CX3CR1GFP/GFP-APCMin mice  
 To confirm that the absence of the CX3CR1 receptor in macrophages was associated to 
increased gut carcinogenesis, we crossed CX3CR1GFP/GFP mice with APCMin mice, which carry a 
mutation in the APC gene leading to the spontaneous development of polyps in the small intestine 
and, upon short DSS administration also in the colonic mucosa. Mice that were either competent 
or not for the expression of CX3CR1 and also carried the APCMin gene were generated. As shown in 
the scheme of Fig. 4A, mice were administered DSS for one week and then water for four weeks.  
As observed in the previous sporadic model of CAC, double-KO mice (CX3CR1GFP/GFP-APCMin) 
showed higher signs of inflammation (higher D.A.I. score and shorter colons) and a greater 
number of polyps compared with WT mice (CX3CR1GFP/+-APCMin) (Fig. 4B-C). Furthermore, 
macrophages and pro-inflammatory monocytes were over-recruited in CX3CR1GFP/GFP-APCMin mice 
(Fig. 4D). The mRNA analysis of the colonic mucosa revealed the same results obtained in the 
AOM-DSS model: the inflammatory cytokines IL-6, IFNγ, and IL-10 were upregulated in KO mice in 
both polyps and colonic tissue (Fig. 4E). Overall, also in a genetic model of gut carcinogenesis, 
magnified by inflammation, KO mice are not able to properly control DSS-triggered colitis and this 
condition results in an aberrant inflammatory response and increased tumor formation.   
The anti-oxidant enzyme Heme-oxygenase-1 is directly induced by the CX3CL1-CX3CR1 axis 
 Heme-oxygenase-1 (HMOX-1) is an enzyme known to have important anti-oxidant and 
anti-inflammatory activities (26-29). We explored the expression of HMOX-1 in the colon tissues of 
WT and KO mice. In all the animal models tested (AOM-DSS, CX3CR1GFP/GFP crossed with APCMin, 
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and recovery from acute colitis), HMOX-1 was significantly down-regulated in KO mice (Fig. 5A). 
The immunofluorescence staining confirmed that CX3CR1-GFP+ cells are the main producers of 
HMOX-1 in the colonic mucosa (Fig. 5B).  
We next investigated if the ligand CX3CL1 was able to induce HMOX-1 production in macrophages. 
In bone marrow derived macrophages, CX3CL1 significantly up-regulated mRNA levels of HMOX-1 
in WT macrophages from CX3CR1+/GFP mice, but no increase was detected in macrophages from 
KO mice (Fig. 5C). Pre-treatment with a blocking anti-CX3CR1 Abs significantly reduced HMOX-1 
expression, indicating a specific effect of the ligand (Fig. 5C). Similar results were found with 
concomitant stimulation of CX3CL1 and LPS that had a strong synergistic effect on HMOX-1 
production in WT, but not in KO macrophages (Fig. 5D).  On the other hand,   CX3CL1 stimulation 
did not affect the production of IL-10 (Fig. 5C and D). Notably, macrophages from KO mice 
produced in vitro higher levels of IL-10, a finding similar to what observed in the in vivo 
experiments (Fig. 5C and D). 
We further confirmed that CX3CL1-treated macrophages from WT mice up-regulated protein 
expression of HMOX-1 by flow cytometry in spleen macrophages (Fig. 5E), and in macrophages 
isolated from the colonic mucosa; this increase was not observed in macrophages from CX3CR1-
deficient mice (Fig. 5F).  
We further examined HMOX-1 production in macrophages and the potential link with signalling 
events down-stream of the CX3CR1 receptor. Upon in vitro stimulation with the ligand CX3CL1, 
macrophages from WT mice showed early phosphorylation of STAT3, a finding previously 
unappreciated, but not of STAT1 (Supplementary Fig. S3); as expected, no phospho-STAT3 was 
detected in macrophages of KO mice (Supplementary Fig. S3).  To corroborate this finding, we 
analysed CX3CL1-induced HMOX-1 expression in WT macrophages pre-treated with the STAT3 
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inhibitor Stattic (1uM). As shown in (Fig. 5G) HMOX-1 up-regulation was reduced upon inhibition 
of STAT3 in macrophages. 
Overall, the experiments demonstrated that HMOX-1 is regulated by the interaction of Fractalkine 
with its receptor CX3CR1, at least partially in a STAT3-dependent manner.  
 
Microbiome influence in colitis-associated cancer 
 HMOX-1 is also involved in the clearance of bacteria in the intestinal lumen by increasing 
phagocytosis. Considering the lower levels of HMOX-1 in KO mice, we tested the in vitro 
phagocytic ability of macrophages from WT and KO mice. The percentage of LPS-coated beads 
internalized by KO macrophages was significantly lower than in control mice (Fig. 6A). We also 
found that the epithelial layer in the adenomatous tissue of KO mice showed a marked down-
regulation of the tight junction protein Zonula Occludens-1 (ZO-1) (Fig. 6A), indicative of a 
damaged barrier. These findings prompted us to analyse the intestinal microbiota of mice treated 
with AOM-DSS, by 16S rRNA gene profiling of fecal metagenomic DNA at day 0 (steady state) and 
at sacrifice (day 70). To study α-diversity, Chao1 coefficient was used as predictor of taxonomic 
richness; in addition, the ecological parameter of β-diversity was evaluated using Unifrac 
algorithms. As shown in Fig. 6B, at day 0 there were no differences in α-diversity between WT and 
KO mice.  In contrast, after the treatment, WT mice displayed higher rate of Chao1 parameter 
compared to KO mice. This may be explained by the excessive immune response generated by 
higher inflammation, reducing bacterial richness. β-diversity analyses allow the comparison of the 
overall taxonomic microbiota composition among samples. We found that, differently from day 0, 
at sacrifice KO mouse samples clustered separately from WT in unweighted Unifrac plot (Fig. 6B), 
indicanting that significant changes in the fecal microbiota composition originated between WT 
and KO mice throughout the DSS-induced inflammation and carcinogenesis process. The relative 
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abundance of specific bacterial taxa was analysed at level of phylum, family and genus in the two 
time points considered. At day 0 almost no differences were detectable between WT and KO; on 
the contrary, at sacrifice, three genera were markedly different between KO and WT samples: 
Akkermansia, Lachnospira and Bacteroides. We tested the abundance of Lachnospira and 
Bacteroides by qPCR but, despite a tendency, no statistically significant differences between WT 
and KO mice were found (Supplementary Fig. S4A-C). On the contrary, qPCR experiments with 
primers targeting the species Akkermansia muciniphila evidenced a significant decrease of this 
bacterium in KO mice at sacrifice (Fig. 6B, right panel), while it was identically represented at day 0 
in untreated WT and KO mice.   
 In order to test if the intestinal microbiota can influence the microenvironment and has an 
impact on the CAC model, we co-housed WT and KO mice. Along the AOM-DSS experiment, weight 
and D.A.I. score were registered every week, as represented in Fig. 6C (left panel).  It was evident 
that the co-housing had a dramatic effect: both WT and KO co-housed mice displayed a lower 
D.A.I. if compared with the classical AOM-DSS experiment (Supplementary Fig. S 4A-C and Fig. 1B); 
furthermore, disease scores did not differ between WT and KO mice. The results clearly indicated 
that gut microbiota of the two strains was able to mutually influence each other and had an 
important effect on the disease. Indeed, A. muciniphila at the end of the experiment had similar 
mRNA levels in co-housed WT and KO mice (Fig. 6C, right panel). Nevertheless, some differences 
remained in terms of number of polyps, which were fewer than in the classical CAC model, bur still 
were significantly more in KO mice than in co-housed WT mice (Fig. 6C, middle panel). 
 To better understand how the co-housing decreased the severity of the disease, we 
extracted mRNA from polyps and determined the levels of both pro and anti-inflammatory 
cytokines. As shown in Fig. 6D, the differences observed in the classical AOM-DSS model between 
WT and KO mice were no longer present and similar levels of TNF, IFNγ and IL-10 were detected. 
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However, HMOX-1 still remained under-expressed in KO mice. Overall, the co-housing experiment 
resulted in an attenuation of the disease severity, lower inflammation and higher capability to 
recover after DSS administration. In this landscape only HMOX-1 was still lower and, indeed, colon 
carcinogenesis was only partially reduced by co-housing. 
 
The pharmacological up-regulation of HMOX-1 protects from prolonged inflammation and colon 
carcinogenesis  
 Based on our results, the excessive mucosal inflammation found in KO mice could be 
ascribed to the reduced levels of HMOX-1 in mice lacking CX3CR1. To corroborate this finding, we 
pharmacologically modulated in vivo levels of HMOX-1 by treating mice with cobalt 
protoporphyrin IX (coPP), and inducer of HMOX-1, or with the inhibitor Zinc protoporphyrin 
(znPP). After administration of znPP, mice receiving 1 cycle of DSS showed a strong increase in the 
severity of the disease already at days 6, compared with vehicle-treated animals, and the disease 
index was still high at day 10, during the recovery phase (Supplementary Fig. S5). Conversely, the 
HMOX-1-inducer coPP completely ablated disease index, ulcer formation and weight loss by day 9-
10 (Supplementary Fig. S5).  The phenotype of znPP-treated mice resulted so severe that it was 
not possible to go longer in time with the experiment. Therefore the AOM-DSS experiment was 
performed with the HMOX-1 inducer coPP. Both CXRCR1GFP/+ and CX3CR1GFP/GFP mice were treated 
with coPP four times a week during the DSS cycles, as detailed in the scheme in Fig. 7A. Strikingly, 
treatment with coPP was able to switch off inflammation also in KO mice compared to vehicle-
treated mice: Disease index scores were close to 0 and KO mice showed a recovery in weight 
similar to that of WT mice (Fig. 7B). At the end of the experiment (day 70), the histological 
analyses revealed that the phenotype of coPP-treated KO mice was totally reverted with no signs 
of inflammation (Supplementary Fig. S6). Moreover, the formation of polyps was almost 
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completely abolished by the treatment (Fig. 7C). Induction of HMOX-1 in the colon of treated mice 
was checked by WB analysis. In vehicle-treated animals, HMOX-1 protein was reduced in KO 
compared to WT mice, as mentioned above (Fig. 7D), but was significantly upregulated in coPP-
treated animals, both in KO and WT mice, with similar levels. The high levels of inflammatory 
mediators found in KO mice were blunted upon coPP treatment, confirming the anti-inflammatory 
effect of HMOX-1 (Fig. 7E).  
 In conclusion, if HMOX-1 is pharmacologically induced the pharmacological stimulation of 
HMOX-1 completely resolved the DSS-induced inflammation and protected mice from 
carcinogenesis. 
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Discussion 
 Chronic inflammation in the gut is strongly implicated in the promotion of carcinogenesis 
and disease progression (30-33). In this study we show that CX3CR1-deficient mice were more 
susceptible in experimental models of intestinal carcinogenesis: colonic tissues were more 
infiltrated by inflammatory monocytes/macrophages and had higher levels of inflammatory 
cytokines. As a result of higher inflammation sustained over time, CX3CR1-KO mice had increased 
tumor load with significantly more adenomatous polyps. The exacerbated colonic inflammation in 
KO mice was not due to impaired IL-10 production, which was actually increased compared to WT 
mice, or to defects of the IL-10R, but to their inability to recover from inflammation.  
 Colon tissues of CX3CR1-KO mice had lower levels of HMOX-1, a crucial anti-inflammatory 
and anti-oxidant enzyme produced by macrophages and other cell types (34-36). HMOX-1 is the 
inducible form of the rate limiting step of conversion of heme into carbon monoxide and biliverdin 
(37,38). The well-known anti-inflammatory and tissue-protective effect of this enzyme was 
observed in patients affected by IBD and in mouse models of colitis (39-42). Up-regulation of 
HMOX-1 results in a better outcome in experimental colitis and its protective effect is the result of 
radical scavenging (28,43). 
 In vitro and ex vivo studies demonstrated that CX3CR1 engagement by its ligand 
CX3CL1/Fractalkine induced HMOX-1 up-regulation in macrophages, via STAT3 phosphorylation. 
This induction was absent in CX3CR1-KO macrophages.  HMOX-1 can be stimulated also by 
bacteria; the combination of LPS and CX3CL1 in vitro had a strong synergistic effect, but in KO mice 
HMOX-1 levels were dramatically lower. During DSS treatment in vivo mice are exposed to a huge 
amount of endotoxin and other microbe-associated molecular patterns, due to disruption of the 
epithelial barrier and bacterial translocation. The finding that HMOX-1 levels in KO mice were 
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lower, indicates that the CX3CL1-CX3CR1 axis is not redundant in the regulation of this enzyme in 
gut macrophages.  
The CX3CR1 receptor in the colonic immune populations is largely expressed by macrophages 
(6,44,45), even though a very minor proportion of DC or activated T cells expressing low levels of 
CX3CR1 has been reported(12,46,47). Nevertheless, in the adenomatous polyps, our results clearly 
demonstrate that CX3CR1 is expressed by virtually all F4/80+ macrophages, and not by CD103+ DC 
or CD3+ T cells (Supplementary Fig. S7).  
Therefore, at least in the context of colon carcinogenesis, the CX3CL1-CX3CR1 axis impacts 
predominantly on gut macrophages for the induction of HMOX-1. 
 Other factors up-regulating HMOX-1 include: heavy metals, hypoxia, thermal shock, free 
radical, heme, NO and IL-10 (48). Many studies suggested a synergism between IL-10 and the 
microbiome in the induction of HMOX-1 (34), (49). It seems that the microbiota and its products 
stimulate HMOX-1 production via IL-10, and the consequent CO formation facilitates bacteria 
clearance by macrophages (50). Lee et al. (48), demonstrated that the up-regulation of HMOX-1 is 
dose-dependently induced by IL-10. In our study, although IL-10 levels were much higher in KO 
mice, this could not compensate the low expression of  HMOX-1.    
The phagocytic ability of KO macrophages was also impaired compared to CX3CR1-expressing cells 
of WT animals, in line with a previous report (51). Furthermore, we observed a profound 
alteration of the epithelial barrier in KO mice with a marked down-regulation of the tight junction 
marker Zo-1. Thus, loss of barrier integrity, coupled with impaired phagocytosis, facilitates 
microbial translocation in tissues, generating inflammation and tissue damage.  
 The analysis of the bacterial taxonomic composition of the intestinal microbiota of mice 
treated with the AOM-DSS protocol indicated that, at steady state, no differences were detected 
between WT and KO mice. At the end of the experiment KO mice had different bacterial 
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composition, with reduced β-diversity, likely due to the exaggerated immune activation. These 
findings are in line with studies in human IBD, where the richness in bacterial species and their 
diversity is reduced during active disease, and also the stability in the composition of microbiota is 
changed (52,53). The metagenomics analyses unveiled that at sacrifice a significant difference was 
found only for Akkermansia. Akkermansia is a bacterial genus that belongs to the Gram negative 
phylum Verrucomicrobia and ascribes so far the only species A. muciniphila. Reportedly, A. 
muciniphila is able to efficiently degrade intestinal mucins and adhere on colonic epithelial cells, 
where it may promote the integrity of the epithelial cell layer (54). Notably, A. muciniphila, which 
is severely impaired during inflammatory bowel diseases, was demonstrated to reduce 
macrophage infiltration, downregulate pro-inflammatory chemokine expression, and attenuate 
metabolic endotoxemia in mice with Western diet-induced inflammation (55). Particularly, the 
reduction in circulating endotoxin level mediated by A. muciniphila was attributed to the induction 
of intestinal expression of tight junction proteins (55). These data are in agreement with the 
results of our study showing higher inflammation and altered intestinal barrier together with 
Akkermansia depletion in CX3CR1-KO mice. Moreover, being the mucus the native habitat of many 
species of bacteria, its alteration results also in a dysregulation of the total microbiome 
composition (56,57). Therefore, the dysregulation observed in KO mice may be the consequence 
of their inability to produce sufficient amounts of HMOX-1 and to properly regulate the 
commensal microbiome and intestinal inflammation.  
 We analysed if the microbiome of WT mice was able to positively influence disease 
behaviour of CX3CR1 KO mice. The results obtained with the co-housing experiment clearly 
indicated that the mixed composition of WT and KO microbiome had a positive effect in limiting 
tumor development, and all the histological and inflammatory parameters were drastically 
ameliorated in KO mice. Importantly, the quantification of Akkermansia in fecal samples revealed 
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the presence of this microorganism also in KO co-housed mice (but not in KO mice housed alone), 
underlying the beneficial role of this bacterium in the prevention of gut inflammation. 
Nevertheless, a significant difference in HMOX-1 production was still observed in co-housed KO 
mice, and more polyps were generated. This finding indicates that, in spite of the relevance of the 
microbiota, a functional CX3CL1-CX3CR1 axis is necessary to produce enough HMOX-1 to control 
inflammation in the intestine. That this enzyme has a crucial role in the protection from tumor 
development   was fully confirmed in experiments where the pharmacological induction of HMOX-
1, by in vivo treatment with coPP, eradicated intestinal inflammation and protected KO mice from 
carcinogenesis. In conclusion, we have shown that HMOX-1 is produced downstream of the 
CX3CL1- CX3CR1 axis in gut macrophages. This pathway is non-redundant and necessary to control 
intestinal inflammation and to prevent the establishment of chronic colitis that leads to tumor 
development. 
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Figure legends 
Figure 1: Colitis-associated carcinogenesis is more severe in CX3CR1 GFP/GFP (KO mice)  
(a) Treatment scheme of the AOM/DSS protocol in CX3CR1GFP/GFP and CX3CR1+/GFP mice. (b) Disease activity index (as 
described in Experimental Procedures) and (c) polyps’ number are higher in KO mice while colon length is shorter.    
(d) immunofluorescence of GFP+ macrophages in the polyps of CX3CR1GFP/GFP and CX3CR1+/GFP mice after treatment 
with AOM/DSS; KO mice have increased infiltration of GFP+ macrophages. (e) Immunofluorescence with anti-F4/80 
(red); newly recruited macrophages (F4/80+ GFPneg) mainly accumulate at the adenomatous border, while resident 
GFP+ macrophages are inside the polyp; several double positive (F4/80+ GFPpos) macrophages are also visible (yellow). 
Magnification 20X, GFP green, DAPI blue. (f) FACS analysis of disaggregated polyps confirms the higher accumulation 
of GFP+ macrophages and inflammatory LyC6hi monocytes (precursors of CX3CR1+ macrophages) in KO mice, while no 
differences were found for LyC6low myeloid cells. (Results on panels b and f are from 1 experiment with 8 mice per 
group, representative of 5 experiments performed with similar results. On panels c and d results are the mean ± SEM 
of 5 experiments. T test *p<0,05, **p<0,01 ***p<0,001 ****p<0,0001)  
 
Figure 2: mRNA expression of pro and anti-inflammatory cytokines in the colonic tissue of CX3CR1+/GFP (WT) and 
CX3CR1GFP/GFP (KO) mice 
Tumoral tissues (polyps) were separated from the rest of the colon and the two specimens were separately analyzed 
for the expression of different pro-inflammatory (a) or anti-inflammatory (b) cytokines. In KO mice the expression of 
several pro-inflammatory mediators in the colons and polyps was higher than in WT mice. The IL-10 family members 
(IL-10, IL-19 and IL-20) were also up-regulated in KO mice (Results are from 1 experiment with 8 mice per group, 
representative of 5 experiments performed with similar results. T test *p<0,05, **p<0,01 ***p<0,001) 
 
Figure 3: CX3CR1GFP/GFP (KO) mice do not recover from acute colitis after DSS treatment 
(a) Treatment scheme of the DSS protocol. (b) Body weight and colon length in WT mice are completely restored at 
day 13, but not in KO mice. (c) Cytokine mRNA expression in the inflamed colonic tissues. IL-10, IL-10R and IL-20 are 
higher in KO mice; pro-inflammatory cytokines are still up-regulated at day 13 in KO mice, while are decreased in 
recovering WT mice. (d) FACS analysis of colon samples revealed a peak of infiltrating leukocytes at day 10 with higher 
recruitment of macrophages (F4/80+ CD11b+ Ly6G-) and inflammatory Ly6Chi monocytes in KO mice. (Results are from 
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1 experiments performed with 4 mice per group for each time point, representative of 5 experiments performed with 
similar results. T Test *p<0,05, **p<0,01, ***p<0,001). 
 
Figure 4: Increased carcinogenesis and inflammation in DSS-treated APCmin- CX3CR1 GFP/GFP mice  
(a) Treatment scheme of the DSS protocol in APCmin mice crossed with CX3CR1GFP/GFP mice.  As it was for the AOM-DSS 
model, KO mice (APCmin -CX3CR1GFP/GFP) show higher signs of inflammation compared to WT mice (APCmin -
CX3CR1+/GFP). (b) Colon length and number of polyps. (c) Disease activity index and body weight. (d) FACS analysis of 
disaggregated polyps. KO mice have higher infiltration of F4/80+ CD11b+ Ly6G- macrophages, as well as of GFP+ 
macrophages and inflammatory Ly6CHi monocytes. (e) Cytokine mRNA expression in the polyps and in colonic tissues. 
KO mice express higher levels of IL-6, IFNγ and IL-10. (On the panel B, results are the mean of 3 experiments. Results 
on panel C, D, E are from 1 experiment with 5 mice per group, representative of 3 experiments performed with similar 
results. T test *p<0,05, **p<0,01 ***p<0,001) 
 
 
 
Figure 5: CX3CR1 signalling induces Heme-oxygenase-1 production 
(a) The mRNA expression of HMOX-1 is reduced in the adenomatous tissue of CX3CR1GFP/GFP KO mice, both in the 
AOM/DSS experiments, in the APCmin model and in the inflamed tissue after the recovery from acute colitis. b) 
Immunofluorescence staining of HMOX-1 (red) in colonic tissue co-localizes with CX3CR1+ macrophages (GFP-green). 
(c) Induction of HMOX-1 and IL-10 upon in vitro treatment of GFP+-sorted BM-derived macrophages stimulated with 
rmCX3CL1 (300ng/ml) and/or LPS (100ng/ml);  rmCX3CL1 activates HMOX-1  expression only in CX3CR1+/GFP WT mice.  
HMOX-1 is strongly inhibited by pre-treatment with anti-CX3CR1 mAb in WT macrophages.  (d)  Low levels of HMOX-1 
are induced by LPS in both WT and KO macrophages, but the strong synergism of combined rmCX3CL1 and LPS is 
observed only in CX3CR1-expressing WT mice. Instead, KO macrophages produce higher levels of IL-10. (e) FACS 
analysis of splenic CX3CR1+/GFP WT macrophages treated for 18 hr with 300 ng/ml of rmCX3CL1 and stained with anti-
HMOX-1.  CX3CL1 treatment (red line) increased HMOX-1 production. (f) FACS analysis of HMOX-1 of gut macrophages 
from isolated lamina propria of WT or KO mice. Cells were treated with rmCX3CL1 as in (e). Cells were gated as 
positive for CD45, CD11b, F4/80, and GFP. Results of HMOX-1 immunopositivity are expressed as fold (MFI) over 
untreated macrophages. (g) FACS analysis with anti-HMOX-1 of splenic CX3CR1+/GFP WT macrophages treated for 18 hr 
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with 300 ng/ml of rmCX3CL1. Pre-treatment with the STAT3 inhibitor Stattic (1uM) inhibited HMOX-1 production.  T 
test *p<0,05, **p<0,01, ***p<0,001  
 
Figure 6: Analysis of intestinal microbiota during AOM/DSS treatment and co-housing experiment of CX3CR1+/GFP 
(WT) and CX3CR1GFP/GFP (KO) mice. 
(a) Phagocytosis of LPS-coated beads by peritoneal macrophages isolated from WT and KO mice.  
Immunofluorescence of the tight junction protein (ZO-1) in colons of AOM/DSS-treated mice. The mucosa of KO mice 
shows less ZO-1 protein expression indicative of a damaged epithelial barrier. (b) Bacterial profiling of the fecal 
microbiota of AOM/DSS-treated mice. Plots of α- and β-diversity in WT and KO mice are similar at day 0 but change 
drastically at sacrifice (Sac). The bacterial genus Akkermansia was scarcely represented at day 0, but highly increased 
at sacrifice only in WT mice.  
(c) AOM/DSS experiment in co-housing conditions of WT and KO mice.  Disease activity index is identical in co-housed 
WT and KO mice and, at sacrifice, similar levels of Akkermansia were detected. Co-housed mice formed fewer polyps, 
nevertheless KO mice had significantly more polyps than WT mice. (d) mRNA levels of pro and anti-inflammatory 
cytokines in the colonic mucosa of co-housed mice were similar in WT and KO mice, but HMOX-1 was still lower in KO 
mice. (Results are from 1 experiment with 8 mice per group, representative of 2 experiments performed with similar 
results. T test *p<0,05, **p<0,01 ***p<0,001) 
 
Figure 7: Treatment with coPP increases HMOX-1 expression and ameliorates inflammation and carcinogenesis   
(a) Treatment scheme of coPP administration during the AOM/DSS protocol. (b) In both WT and KO mice coPP 
administration strongly reduces disease activity index and body weight, (c) number of polyps, colitis score and colon 
shortness. (d) Western blot to detect HMOX-1 in the colons of coPP-treated mice.  Treatment increases HMOX-1 
production in WT and KO mice. Vehicle-treated KO mice show lower production of HMOX-1 compared to WT mice.   
(e) mRNA expression of pro-inflammatory cytokines in colon tissue is higher in vehicle-treated KO mice, and strongly 
reduced upon treatment with coPP. (Results are from 1 experiment, representative of 3 experiments performed with 
similar results. On panel C results are the mean of 3 experiments. T test *p<0,05, **p<0,01 ***p<0,001)    
 







